Peritoneal dialysis and inflammation

Krediet, 1999, The effect of various dialysis solutions on peritoneal membrane viability, Perit Dial Int, 19, S257, 10.1177/089686089901902S43 Jörres, 2012, Novel peritoneal dialysis solutions—what are the clinical implications?, Blood Purif, 33, 153, 10.1159/000334151 2006, Clinical practice guidelines for peritoneal dialysis adequacy, Am J Kidney Dis, 48, S98 Daugirdas, 2008, Fisiologia da diálise peritoneal, 297 Toma, 2010, Peritoneal transport testing, Maedica (Buchar), 5 Twardowski, 1989, Clinical value of standardized equilibration tests in CAPD patients, Blood Purif, 7 Stankovic-Popovic, 2011, Effects of conventional versus biocompatible peritoneal dialysis solutions on peritoneal and systemic inflammation, malnutrition and atherosclerosis in CAPD patients, Clin Nephrol, 76, 314, 10.5414/CN106991 Lai, 2010, Inflammation in peritoneal dialysis, Nephron Clin Pract, 116, C11, 10.1159/000314544 Cadima Vicente, 2008, Efeito da glicose na histomorfologia do peritônio durante a diálise peritoneal, HU Revista, 34, 27 Yung, 2011, Pathophysiology of the peritoneal membrane during peritoneal dialysis: the role of hyaluronan, J Biomed Biotechnol, 1, 10.1155/2011/180594 Nagy, 1996, Peritoneal membrane morphology and function, Kidney Int, 50, S2 Schmitt, 2011, Solutions for peritoneal dialysis in children: recommendations by the European Pediatric Dialysis Working Group, Pediatr Nephrol, 26, 1137, 10.1007/s00467-011-1863-4 Gusmao, 2010, Malnutrition, inflammation and other risk factors for cardiovascular diseases in patients undergoing peritoneal dialysis, Rev De Nutricao Braz J Nutr, 23, 335 Papagianni, 2004, Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis, Nephrol Dial Transplant, 19, 1258, 10.1093/ndt/gfh078 Mortier, 2002, Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products, J Am Soc Nephrol, 13, 480, 10.1681/ASN.V132480 Baroni, 2012, Inflammation and the peritoneal membrane: causes and impact on structure and function during peritoneal dialysis, Mediators Inflamm, 2012, 1, 10.1155/2012/912595 Witowski, 2003, Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se, Perit Dial Int, 23, 381, 10.1177/089686080302300412 Boulanger, 2008, Peritoneal and systemic inflammation: the benefits of using biocompatible peritoneal dialysis fluids, Perit Dial Int, 28, 28, 10.1177/089686080802800106 Boulanger, 2004, The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products, Nephrol Dial Transplant, 19, 2208, 10.1093/ndt/gfh277 De Vriese, 2003, Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane, J Am Soc Nephrol, 14, 2109, 10.1681/ASN.V1482109 Pecoits, 2006, Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis, Perit Dial Int, 26, 53, 10.1177/089686080602600109 Pecoits-Filho, 2002, Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate, Nephrol Dial Transplant, 17, 1480, 10.1093/ndt/17.8.1480 Lee, 2010, Proinflammatory cytokines, hepatocyte growth factor and adipokines in peritoneal dialysis patients, Artif Organs, 34, E222, 10.1111/j.1525-1594.2010.01000.x Sawai, 2011, Peritoneal macrophage infiltration is correlated with baseline peritoneal solute transport rate in peritoneal dialysis patients, Nephrol Dial Transplant, 26, 2322, 10.1093/ndt/gfq702 Szeto, 2007, Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—a 1-year randomized control trial, Nephrol Dial Transplant, 22, 552, 10.1093/ndt/gfl559 Pajek, 2008, Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study, Perit Dial Int, 28, 44, 10.1177/089686080802800109 Ahmad, 2006, Impact of new dialysis solutions on peritonitis rates, Kidney Int, 70, S63, 10.1038/sj.ki.5001917 Lui, 2012, A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial, Am J Kidney Dis, 60, 966, 10.1053/j.ajkd.2012.05.018 Maksic, 2009, Systemic and intraperitoneal proinflammatory cytokine profiles in patients on continuous ambulatory peritoneal dialysis, Adv Perit Dial, 25 Alsop, 1994, History, chemical and pharmaceutical development of icodextrin, Perit Dial Int, 14, 5, 10.1177/089686089401402S01 Dombros, 2005, European best practice guidelines for peritoneal dialysis Lin, 2009, Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid, Clin J Am Soc Nephrol, 4, 1799, 10.2215/CJN.02950509 Cho, 2013, Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials, Nephrol Dial Transplant, 9 Martikainen, 2005, Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane?, Perit Dial Int, 25, 453, 10.1177/089686080502500509 Moriishi, 2008, Icodextrin and intraperitoneal inflammation, Perit Dial Int, 28, S96, 10.1177/089686080802803s19 Parikova, 2003, Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions, Adv Perit Dial, 19, 186 Lin, 2009, Icodextrin dialysate improves nutritional and inflammatory profiles in peritoneal dialysis patients, Ren Fail, 31, 98, 10.1080/08860220802595500 Davies, 2008, Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange, Nephrol Dial Transplant, 23, 2982, 10.1093/ndt/gfn176 Huxtable, 1992, Physiological actions of taurine, Physiol Rev, 72, 101, 10.1152/physrev.1992.72.1.101 Nishimura, 2009, Evaluation of taurine as an osmotic agent for peritoneal dialysis solution, Perit Dial Int, 29, 204, 10.1177/089686080902900216 Higuchi, 2006, Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis, Ther Apher Dial, 10, 372, 10.1111/j.1744-9987.2006.00391.x